Home » Stocks » Monopar Therapeutics

Monopar Therapeutics, Inc. (MNPR)

Stock Price: $5.00 USD 0.20 (4.17%)
Updated Oct 26, 2020 3:03 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 53.68M
Revenue (ttm) n/a
Net Income (ttm) -4.48M
Shares Out 10.74M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $5.00
Previous Close $4.80
Change ($) 0.20
Change (%) 4.17%
Day's Open 4.85
Day's Range 4.80 - 5.10
Day's Volume 39,109
52-Week Range 4.77 - 48.00

More Stats

Market Cap 53.68M
Enterprise Value 41.26M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 10.74M
Float 2.63M
EPS (basic) -0.45
EPS (diluted) -0.42
FCF / Share -0.32
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 45,580
Short Ratio 1.34
Short % of Float 1.73%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.28
Revenue n/a
Operating Income -4.58M
Net Income -4.48M
Free Cash Flow -3.40M
Net Cash 12.42M
Net Cash / Share 1.16
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -31.15%
ROE -51.84%
ROIC 2,115.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$31.00*
(520.00% upside)
Low
11.0
Current: $5.00
High
42.0
Target: 31.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-4.32-3.33-16.60-1.19
Net Income-4.22-3.23-16.55-1.19
Shares Outstanding9.329.298.789.29
Earnings Per Share-0.45-0.35-1.89-
Operating Cash Flow-3.02-2.68-2.63-1.19
Free Cash Flow-3.02-2.68-2.63-1.19
Cash & Equivalents13.216.899.782.87
Net Cash / Debt13.216.899.782.87
Assets13.357.329.932.90
Liabilities0.720.400.310.06
Book Value12.636.929.622.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Monopar Therapeutics, Inc.
Country United States
Employees 6
CEO Chandler Drew Robinson

Stock Information

Ticker Symbol MNPR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MNPR
IPO Date December 19, 2019

Description

Monopar Therapeutics, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.